Expression of c-myc, Epidermal Growth Factor Receptor and c-erbB-2 in Human Endometrial Carcinoma and Cervical Adenocarcinoma.

Abstract

SATO, S., ITO, K., OZAWA, N., YAJIMA, A. and SASANO, H. Expression of c-myc, Epidermal Growth Factor Receptor and c-erbB-2 in Human Endometrial Carcinoma and Cervical Adenocarcinoma. Tohoku J. Exp. Med., 1991, 165 (2), 137-145-Thirty specimens of human endometrial carcinoma (n=23) and cervical adenocarcinoma (n=7) have been analyzed for c-myc, epidermal growth factor receptor (EGFR) and c-erbB-2 by immunohistochemistry. In endometrial carcinomas, expression of c-myc was observed in all cases, EGFR in 21 of 23 cases (91.3%) and c-erbB-2 in 7 of 23 cases (30.4%). In cervical adenocarcinomas, expression of c-myc was seen in 5 of 7 cases (71.6%), EGFR in all cases and c-erbB-2 in 2 of 7 cases (28.6%). c-myc immunoactivity was observed as nuclear or cytoplasmic stain or both, EGFR as membrane and cytoplasmic stain, c-erbB-2 as menbrane stain. There was no relationship between expression of these three oncogenes and clinical prognostic factors in the present study.